# Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

> **NCT06529731** · PHASE2 · RECRUITING · sponsor: **Sawa Ito, MD** · enrollment: 45 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Interferon gamma-1b
- **BIOLOGICAL:** Donor Leukocyte Infusion (DLI)

## Key facts

- **NCT ID:** NCT06529731
- **Lead sponsor:** Sawa Ito, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-23
- **Primary completion:** 2027-10-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-10-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06529731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06529731, "Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06529731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*